Showing results (141-150 of 194) with videos related to
Sort By:
Pageof 20
Brain, Behavior, and Immunity|October 22, 2022
Mitochondrial redox environments predict sensorimotor brain-behavior dynamics in adults with HIVRachel K Spooner, Brittany K Taylor, Iman M Ahmad, et al.Hepatology (Baltimore, Md.)|October 24, 2006
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Marion G Peters, Janet Andersen, Patrick Lynch, et al.The Patient|May 31, 2021
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)Vasiliki Chounta, Edgar T Overton, Anthony Mills, et al.AIDS and Behavior|May 16, 2020
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 TrialsAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.Journal of Neuroimmunology|May 12, 2005
Development of a rapid autopsy program for studies of brain immunityAnuja Ghorpade, Leslie Bruch, Yuri Persidsky, et al.The Journal of Infectious Diseases|July 20, 2012
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted miceUpal Roy, JoEllyn McMillan, Yazen Alnouti, et al.Molecular Cell|April 23, 2016
Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLAAndrew M Gross, Philipp A Jaeger, Jason F Kreisberg, et al.BMC Health Services Research|March 21, 2021
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trialsAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.Culture, Health & Sexuality|May 22, 2020
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and SpainAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.The Journal of Infectious Diseases|February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesTimothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.Pageof 20